Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Paul Franks

Paul Franks

Principal investigator

Paul Franks

A Mendelian randomization study of circulating uric acid and type 2 diabetes.

Author

  • Ivonne Sluijs
  • Michael V Holmes
  • Yvonne T van der Schouw
  • Joline Wj Beulens
  • Folkert W Asselbergs
  • José María Huerta
  • Tom M Palmer
  • Larraitz Arriola
  • Beverley Balkau
  • Aurelio Barricarte
  • Heiner Boeing
  • Françoise Clavel-Chapelon
  • Guy Fagherazzi
  • Paul Franks
  • Diana Gavrila
  • Rudolf Kaaks
  • Kay Tee Khaw
  • Tilman Kühn
  • Esther Molina-Montes
  • Lotte Maxild Mortensen
  • Peter Nilsson
  • Kim Overvad
  • Domenico Palli
  • Salvatore Panico
  • J Ramón Quirós
  • Olov Rolandsson
  • Carlotta Sacerdote
  • Núria Sala
  • Julie A Schmidt
  • Robert A Scott
  • Sabina Sieri
  • Nadia Slimani
  • Annemieke Mw Spijkerman
  • Anne Tjonneland
  • Ruth C Travis Dphil
  • Rosario Tumino
  • Daphne L van der A
  • Stephen J Sharp
  • Nita G Forouhi
  • Claudia Langenberg
  • Elio Riboli
  • Nicholas J Wareham

Summary, in English

We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.

Department/s

  • Genetic and Molecular Epidemiology
  • Internal Medicine - Epidemiology
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2015

Language

English

Pages

3028-3036

Publication/Series

Diabetes

Volume

64

Issue

8

Document type

Journal article

Publisher

American Diabetes Association Inc.

Topic

  • Endocrinology and Diabetes

Status

Published

Research group

  • Genetic and Molecular Epidemiology
  • Internal Medicine - Epidemiology

ISBN/ISSN/Other

  • ISSN: 1939-327X